Kura Oncology: Commercialization In AML Presents Uneven Upside (NASDAQ:KURA)
Brendan, a Pennsylvanian by start:-Accomplished a Ph.D. at Stanford College within the area of natural synthesis (2009). -Labored for a significant pharmaceutical firm (Merck, 2009-2013).-Labored in biotech together with start-ups (Theravance/Aspira) previous to securing employment at Caltech.-First worker and co-founder of 1200 Pharma because it spun out of Caltech garnering main funding (into the 8 figures).-Stays an avid investor, centered on market tendencies and particularly biotechnology shares.
Analyst’s Disclosure: I/we have now a helpful lengthy place within the shares of KURA both by means of inventory possession, choices, or different derivatives. I wrote this text myself, and it expresses my very own opinions. I’m not receiving compensation for it (apart from from Searching for Alpha). I’ve no enterprise relationship with any firm whose inventory is talked about on this article.
The creator has a helpful lengthy place in each KURA and SNDX.
Searching for Alpha’s Disclosure: Previous efficiency is not any assure of future outcomes. No suggestion or recommendation is being given as as to whether any funding is appropriate for a selected investor. Any views or opinions expressed above might not replicate these of Searching for Alpha as a complete. Searching for Alpha is just not a licensed securities seller, dealer or US funding adviser or funding financial institution. Our analysts are third social gathering authors that embrace each skilled buyers and particular person buyers who will not be licensed or licensed by any institute or regulatory physique.
